TW197439B - - Google Patents

Info

Publication number
TW197439B
TW197439B TW081102387A TW81102387A TW197439B TW 197439 B TW197439 B TW 197439B TW 081102387 A TW081102387 A TW 081102387A TW 81102387 A TW81102387 A TW 81102387A TW 197439 B TW197439 B TW 197439B
Authority
TW
Taiwan
Prior art keywords
halogen
oxoalkyl
prostaglandins
phosphonate
beta
Prior art date
Application number
TW081102387A
Other languages
English (en)
Chinese (zh)
Original Assignee
Ueno Pharmaceutics Applic Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Pharmaceutics Applic Res Co Ltd filed Critical Ueno Pharmaceutics Applic Res Co Ltd
Application granted granted Critical
Publication of TW197439B publication Critical patent/TW197439B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW081102387A 1991-04-04 1992-03-28 TW197439B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7148391 1991-04-04

Publications (1)

Publication Number Publication Date
TW197439B true TW197439B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-01-01

Family

ID=13461939

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081102387A TW197439B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-04-04 1992-03-28

Country Status (11)

Country Link
US (1) US5229529A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0507625B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH089608B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR970003125B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE141921T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2064481C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69213067T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0507625T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2093776T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3020903T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW197439B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0643051T3 (da) * 1992-09-30 2000-04-17 R Tech Ueno Ltd Fremgangsmåde til fremstilling af alfa,beta-umættede ketoner
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
JP4358940B2 (ja) * 1999-08-26 2009-11-04 丸善石油化学株式会社 シクロヘキサンラクトン構造を有する重合性化合物及び重合体
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030054036A1 (en) * 2001-03-13 2003-03-20 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
JP2004532847A (ja) * 2001-04-20 2004-10-28 ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア 疎水性薬物のためのミセル薬物送達システム
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
DE10220729A1 (de) * 2002-05-08 2003-11-20 Martin Foerster Verfahren zum Bestimmen einer von Tieren gesoffenen Menge an flüssigen Nahrungsmitteln
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
AU2005273968A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006089209A2 (en) * 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
CA2637797C (en) * 2006-02-07 2015-03-17 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
MX2008011978A (es) 2006-03-22 2009-04-22 Medigene Ag Tratamiento del cancer de seno negativo al triple receptor.
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8409601B2 (en) * 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
WO2009143454A2 (en) 2008-05-22 2009-11-26 Kereos, Inc. Combination antitumor therapy
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8389522B2 (en) 2008-10-28 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
CA2750487A1 (en) 2009-01-22 2010-07-29 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
CN104582717B (zh) 2012-07-19 2018-03-13 雷德伍德生物科技股份有限公司 对cd22有特异性的抗体及其使用方法
JP2016500058A (ja) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス， インコーポレイテッド 化合物および抱合体を生成するための方法
LT2956175T (lt) 2013-02-15 2017-12-11 The Regents Of The University Of California Chimerinis antigeno receptorius ir jo panaudojimo būdai
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
PL3107899T3 (pl) 2014-02-19 2021-01-25 Aviv Therapeutics, Inc. Policykliczne amidy wiążące mitochondrialną dehydrogenazę aldehydową-2 (aldh2) i ich zastosowanie w leczeniu nowotworów
CN108135917B (zh) 2015-09-25 2021-07-09 Zy医疗 基于包含多糖-维生素缀合物的颗粒的药物制剂
US10654875B2 (en) 2015-11-12 2020-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
KR20180135458A (ko) 2016-04-26 2018-12-20 알.피.쉐러 테크놀러지즈 엘엘씨 항체 컨쥬게이트 및 이의 제조 및 이용 방법
DK3463308T3 (da) 2016-06-01 2022-01-31 Servier Ip Uk Ltd Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
KR20190130559A (ko) 2017-01-18 2019-11-22 에프1 온콜로지, 인코포레이티드 Axl 또는 ror2에 대한 키메라 항원 수용체 및 이의 사용 방법
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CN111065623B9 (zh) 2017-05-24 2024-10-25 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
EA202091832A1 (ru) 2018-01-31 2021-01-11 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная терапия злокачественных новообразований макроциклическим кольцевым комплексом пентаазы и противоопухолевым агентом на основе платины
WO2019195596A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
AU2019249215A1 (en) 2018-04-06 2020-10-22 The Regents Of The University Of California Methods of treating EGFRvIII expressing glioblastomas
WO2019200181A1 (en) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
TW202038994A (zh) 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
WO2020165730A1 (en) 2019-02-14 2020-08-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
KR20220004653A (ko) 2019-04-02 2022-01-11 켄조케티 바이오테크놀러지 인코포레이티드 유출 펌프-암 항원 다중특이적 항체 및 그것과 관련된 조성물, 시약, 키트 및 방법
BR112022011158A2 (pt) 2019-12-12 2022-08-30 Ignite Immunotherapy Inc Vírus vaccinia oncolítico variante e métodos de uso do mesmo
CN115023443A (zh) 2020-01-29 2022-09-06 肯乔克蒂生物技术股份有限公司 抗mdr1抗体及其用途
AU2021284240A1 (en) 2020-06-04 2022-12-08 William Robert ARATHOON Anti-ABCG2 antibodies and uses thereof
CA3182969A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
BR112023000650A2 (pt) 2020-07-14 2023-01-31 Pfizer Vírus vaccinia recombinante
JP2023539883A (ja) 2020-09-02 2023-09-20 ケンジョッケティ バイオテクノロジー，インク． 抗ａｂｃｃ１抗体及びその使用
US20240010747A1 (en) 2020-11-13 2024-01-11 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
EP4247829A1 (en) 2020-11-20 2023-09-27 R.P. Scherer Technologies, LLC Glycoside dual-cleavage linkers for antibody-drug conjugates
AU2022413942A1 (en) 2021-12-13 2024-05-30 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032576A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1976-01-08 1977-06-28
DE2655004C3 (de) * 1976-12-02 1980-06-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von bicyclischen Laktonen
EP0219580B1 (en) * 1985-09-18 1989-11-29 The Upjohn Company Stereo-selective reduction
JPS62153259A (ja) * 1985-12-26 1987-07-08 Sagami Chem Res Center （２−クロロ−３−オキソ−１−アルケニル）−ビシクロ〔３．３．０〕オクテン誘導体及びその製法
DE3620442A1 (de) * 1986-06-18 1987-12-23 Merck Patent Gmbh Ketolactone
EP0394263B1 (en) * 1987-09-04 1994-03-16 The Upjohn Company Process for production of prostaglandin intermediates

Also Published As

Publication number Publication date
KR920019771A (ko) 1992-11-20
KR970003125B1 (ko) 1997-03-14
DK0507625T3 (da) 1996-09-16
DE69213067T2 (de) 1997-01-16
EP0507625B1 (en) 1996-08-28
CA2064481C (en) 1996-12-24
DE69213067D1 (de) 1996-10-02
JPH0592965A (ja) 1993-04-16
CA2064481A1 (en) 1992-10-05
US5229529A (en) 1993-07-20
JPH089608B2 (ja) 1996-01-31
ES2093776T3 (es) 1997-01-01
ATE141921T1 (de) 1996-09-15
GR3020903T3 (en) 1996-11-30
EP0507625A1 (en) 1992-10-07

Similar Documents

Publication Publication Date Title
TW197439B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HUT70593A (en) Process for the preparation of pirimidine compounds
UA5954A1 (uk) Спосіб отримання (+)-4-ді-(н-пропіл)-аміно-6-карбамоіл-1,3,4,5-тетрагідробенз (с,д) індола або його фармацевтично придатної солі
EP0165458A3 (en) (+)-ambrox, process for production thereof and use thereof
EP0312395A3 (en) Production of high surface area carbon fibres
ES2122905A1 (es) Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato).
EP0161574A3 (en) New b-carboline-3-oxadiazolyl derivatives, method of preparing the same and their use
GR3030718T3 (en) Novel prostaglandin analogue.
CA2044498A1 (en) Process for the preparation of dialkyl, pyridine-2,3-dicarboxylates and derivatives thereof from dialkyl dichlorosuccinate
ES2086065T3 (es) Preparacion de tetrahidropiridinas sustituidas.
NO922321D0 (no) Bis(fluormetyl)eter, fremgangsmaate for fremstilling, samtfremgangsmaate for fremstilling av difluormetan av bis(fluormetyl)eter
HUT38623A (en) Process for production of derivatives of n-substituated neuramin-acid
EP0406211A3 (en) Fucosidase inhibitors
ES2057289T3 (es) Procedimiento para la obtencion de octadienoles.
AU624962B2 (en) Ghilanten: antimetastatic principle from the south american leech, haementeria ghilanii
ES8203877A1 (es) Procedimiento de obtencion de nuevos aminoderivados en posi-cion 1, del 1-(3',4'-metilendioxifenil)propan-2-ol
GR1001203B (el) Μεθοδος παρασκευης της ενωσεως 24r-σκυμνολη.
ES2012576A6 (es) Agente de encolado para papel.
IL101052A (en) Process for producing glyceraldehyde- 3-pentanide
ES2120098T3 (es) Procedimiento y productos intermedios para la preparacion de 5-oxaespiro(2.4)heptan-6-ona.
AU549872B2 (en) 4-oxymethyl-5-acyl-1,3-dihydro-2h-imidazol-2-ones
HU9200745D0 (en) Process for the production of 2,2-dimethyl-2,3-dihydro-benzofurane-7-carbonic acid derivatives
DE3470304D1 (en) A process for the preparation of 1,5-diprotected-1,5,10-triazadecane, intermediates thereof and their preparation
CA2066330A1 (fr) Procede de purification de la pseudo-ionone
MX9205610A (es) Procedimiento para la preparacion de: acido (+ -)-2(6-metoxi-2-naftil)-propionico.